Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation
Status:
Completed
Trial end date:
2018-01-16
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and
tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) in hepatitis C
virus (HCV)-infected adults who are undergoing liver transplantation.
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir